Immunotec Inc. said its normalized net income for the fiscal second quarter ended April 30 came to C$633,090, a gain from C$267,070 in the prior-year period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin rose to 2.5% from 1.3% in the year-earlier period.

Total revenue climbed 28.1% on an annual basis to C$25.6 million from C$20.0 million, and total operating expenses climbed 26.9% on an annual basis to C$23.8 million from C$18.7 million.

Reported net income grew 61.9% year over year to C$559,280, or 1 cents per share, from C$345,510, or 0 cents per share.